Dyne advances muscular dystrophy pipeline; BLA submission set for Q2

Dyne Therapeutics (NASDAQ:DYN) ended the first quarter of 2026 with $972.2 million in cash, cash equivalents, and marketable securities.

The company stated this capital provides a financial runway into the first quarter of 2028, covering several critical regulatory and clinical inflection points across its muscle-disease portfolio.

The company's most immediate milestone is the planned submission of a Biologics License Application (BLA) for z-rostudirsen (formerly DYNE-251) in Duchenne muscular dystrophy (DMD).

Following successful results from the DELIVER trial—which showed a sevenfold increase in dystrophin expression—Dyne expects to file for U.S. accelerated approval in the second quarter of 2026.

A potential commercial launch is targeted for the first quarter of 2027.

In its myotonic dystrophy type 1 (DM1) program, Dyne has initiated the Phase 3 HARMONIA trial for z-basivarsen (formerly DYNE-101).

The study is designed to serve as a confirmatory trial for traditional approval and will assess multi-system efficacy, including strength and balance.

Management indicated that z-basivarsen is tracking toward a potential market entry in early 2028.

Both candidates utilize Dyne’s proprietary FORCE platform, which is engineered to overcome systemic delivery challenges by targeting therapeutic payloads directly to skeletal, cardiac, and smooth muscle tissue.